High-Throughput Screening

High-Throughput Screening

It is a method of an experiment for scientists used in the discovery of the drug, moreover, it is an interlinking bond between biology and chemistry. This technique uses artificial intelligence, robots and computer software which allows us to conduct many pharmacological tests at a very small pace of time and accurately. This process can help to identify an active compound, gene, and protein.

History:

It has its origin from natural products in 1986, by replacing synthetic compound of dimethyl sulfoxide with fermentation broths by decreasing assay volume up to 100 microlitres and 96 well plates. In 1989, the process reached a constant state by producing 7200 substances each week.

For almost 40% discovery portfolio HTS gave rise to “hits” by the year 1992. In 1995, it included the ADME target and by the year 1996, almost 90 molecules were tested for protein binding, stability parameters, etc. Similarly, the mutagenic assay was developed and in 1999 ADME HTS completely came under the discovery cycle.

Advantage:

  • To screen many kinds of active compounds such as natural products, combinatorial libraries.
  • To screen array-like DNA, RNA and protein chips.
  • High speed of the assay
  • Highly sensitive processes.
  • Reproducible results.
  • Effective to determine the ADME part of any drug or molecule.

Disadvantage:

  • High cost
  • Low quality
  • Contamination chances are very less
  • Require pure product
  • Require the attention and safety of the product.

Leave a Reply

Your email address will not be published.